Existing users Log In New users Sign up


Immunotherapy for Melanoma Brain Metastases

DISCOVERIES (ISSN 2359-7232), 2019, April-June issue

CITATION: 

Fernandes GNC. Immunotherapy for Melanoma Brain Metastases. Discoveries 2019, 7(2); e93. DOI:10.15190/d.2019.6

Submitted: June 5th, 2019; Revised: June 24th, 2019; Accepted: June 25th, 2019; Published: June 26th, 2019; 

 GO BACK to 2019, April-June issue

 GO BACK to DISCOVERIES

Immunotherapy for Melanoma Brain Metastases

Gil Nuno Castro Fernandes *

Comenius University, Faculty of Medicine, Bratislava, Slovakia;

*Corresponding authors: Gil Nuno Castro Fernandes, MS, Comenius University, Sasinkova 4, 813 72 Bratislava, Slovakia; Email: gilcastrofernandes@hotmail.com

Abstract

Brain metastases are about ten times more frequent than a brain primary tumor, being present in 20-40% of adults with systemic cancer. Together with lung cancer and breast cancer, skin cancers such as melanoma are top primary tumors which metastasizes to the brain. Advanced melanoma is well known for its propensity to metastasize to the brain, with 80% of patients presenting brain metastasis at the autopsy. However, current therapies are not very efficient and brain metastases are in most of the cases lethal. Treatment of melanoma brain metastases with surgery and/or radiation therapy results in a median overall survival of only about four months after diagnosis. New immunotherapies such as targeted or immunomodulatory drugs, many in clinical trials, have shown promise, with some immunomodulatory drugs being able to at least double the overall survival rates for patients with melanoma brain metastases. This review focuses on the recent advances and future potential of using immunotherapy, such as the newly developed immunomodulatory drugs, for melanoma brain metastases therapy. Immunomodulatory drugs bring a great promise as new tools for melanoma treatment in particular and for the treatment of other types of malignancies in general.

Access full text of the manuscript here: 

References

1. Langley RR, Fidler IJ. The biology of brain metastasis. Clin Chem. 2013 Jan;59(1):180-9. doi: 10.1373/clinchem.2012.193342.
2. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003 Dec;29(6):533-40.
3. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996 Jul;7(3):337-44.
4. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin. 2003 Feb;21(1):1-23, vii.
5. Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AK, Vlahovic G, Blackwell KL, Kirkpatrick JP, Fecci PE. Embracing rejection: Immunologic trends in brain metastasis. Oncoimmunology. 2016 Apr 11;5(7):e1172153.
6. Cruz-Muñoz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Semin Cancer Biol. 2011 Apr;21(2):123-30.
7. Jindal V, Gupta S. Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors. Mol Neurobiol. 2018 Aug;55(8):7072-7078.
8. Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS et al. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. Cancer Immunol Res. 2018 Sep;6(9):1039-1045.
9. American Cancer Society. What is Cancer Immunotherapy. Accessed in June 2019: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/what-is-immunotherapy.html
10. Soare GR, Soare CA. Immunotherapy for Breast Cancer:  First FDA Approved Regimen. Discoveries 2019, 7(1); e91. DOI:10.15190/d.2019.4.
11. Chang L, Chang M, Chang HM, Chang F. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e15-e21.
12. Puhalla S, Elmquist W, Freyer D, Kleinberg L, Adkins C, Lockman P et al. Unsanctifying the sanctuary: challenges and opportunities with brain metastases. Neuro Oncol. 2015 May;17(5):639-51.
13. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011 Apr 15;117(8):1687-96.
14. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Nov;19(11):1423-37.
15. Chen Q, Boire A, Jin X, Valiente M, Er EE, Lopez-Soto A et al. Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature. 2016 May 26;533(7604):493-498.
16. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015 Jun 29;212(7):991-9.
17. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337-41.
18. Louveau A, Harris TH, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015 Oct;36(10):569-577.
19. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009 Apr;1788(4):842-57.
20. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2015 Jun 9;5(1):e1057388.
21. Quail DF, Joyce JA. The Microenvironmental Landscape of Brain Tumors. Cancer Cell. 2017 Mar 13;31(3):326-341.
22. Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015 Dec 3;528(7580):93-8.
23. Lin X, DeAngelis LM. Treatment of Brain Metastases. J Clin Oncol. 2015 Oct 20;33(30):3475-84.
24. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010 Apr 13;102(8):1213-8.
25. Cohen JV, Kluger HM. Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol. 2016 Mar 9;6:49.
26. Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 2016 Oct;18(10):1338-49.
27. Owyong M, Hosseini-Nassab N, Efe G, Honkala A, van den Bijgaart RJE, Plaks V et al. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. Drug Resist Updat. 2017 Nov;33-35:23-35.
28. Nowak-Sadzikowska J, Walasek T, Jakubowicz J, Blecharz P, Reinfuss M. Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Rep Pract Oncol Radiother. 2016 May-Jun;21(3):271-7.
29. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014 Apr;15(4):387-95..
30. Glitza Oliva I, Tawbi H, Davies MA. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J. 2017 Jan/Feb;23(1):68-74.
31. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011 Jun 30;364(26):2507-16.
32. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358-65.
33. Aim at Melanoma Foundation. FDA Approved Drugs. Accessed in June 2019: https://www.aimatmelanoma.org/melanoma-treatment-options/fda-approved-drugs-for-melanoma/
34. Cancer Research Institute, Jedd D. Wolchok. Immunotherapy for Melanoma: How is Immunotherapy Changing the Outlook for Patients with Melanoma? Accessed in June 2019: https://www.cancerresearch.org/immunotherapy/cancer-types/melanoma
35. Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol. 2012 Feb 1;83(3):305-14.
36. McQuade J, Davies MA.Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Manag. 2015;2(3):241-254.
37. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 8;366(10):925-31.
38. Kamath SD, Kumthekar PU. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. Front Oncol. 2018 Sep 27;8:414.
39. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J Clin Oncol. 1999 Jul;17(7):2105-16.
40. Brigham and Women's Hospital. Immunotherapy doubles survival rates for patients with melanoma brain metastases. Accessed in June 2019: https://medicalxpress.com/news/2018-07-immunotherapy-survival-patients-melanoma-brain.html
41. Shevach EM. Biological functions of regulatory T cells. Adv Immunol. 2011;112:137-76.
42. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42.
43. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012 Aug;117(2):227-33.

News & Events Latest news from Discoveries

  • 2021, July| 2021, Jul-Aug

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays in the months of July and August 2021. We will get back to the normal processing and publication times starting in September 2021. Note that our editorial and administrativ work is fully funded by the publishing house at this time and we are striving to KEEP THE NO FEE strategy in place as long as possible. 

  • 2021, January| 2021 AWARDS!

    2021 DISCOVERIES AWARDS! Discoveries will offer a $1000 award and several $400 awards in Jan 2022, for the most cited (2021 ISI Citations) and visible (Altmetric Score) articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

    CrossRef
  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.